MicroStockProfit.com releases investment report on Discovery Laboratories

May 20 2010

MicroStockProfit.com announces an investment report featuring Discovery Laboratories Inc. (Nasdaq:DSCO).  The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. 

The full report is available at: www.microstockprofit.com/ads/DSCO

Discovery Laboratories Inc. (DSCO) is a biotechnology company developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases.  Its novel technology (KL4 Surfactant Technology) produces a synthetic, peptide-containing surfactant (KL4 Surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for survival and normal respiratory function.  In addition, its capillary aerosol generating technology (Capillary Aerosolization Technology) produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 Surfactant to the deep lung.  The Company focuses on developing its products, Surfaxin, Surfaxin LS and Aerosurf, to address the most significant respiratory conditions affecting pediatric populations.

Message Board Search for DSCO: http://www.boardcentral.com/boards/DSCO

In the report, the analyst notes:

"For the quarter ended December 31, 2009, the Company reported a net loss of $6.1 million (or $0.05 per share) on 125.6 million weighted average common shares outstanding compared to a net loss of $8.5 million (or $0.08 per share) on 100.5 million weighted average common shares outstanding for the same period in 2008.  

"DSCO recently announced that the revalidation of its optimized fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) has been completed, having met all pre-specified acceptance criteria."